176 related articles for article (PubMed ID: 37998841)
1. Long-Term Suppressive Therapeutic-Drug-Monitoring-Guided Dalbavancin Therapy for Cardiovascular Prosthetic Infections.
Gallerani A; Gatti M; Bedini A; Casolari S; Orlando G; Puzzolante C; Franceschini E; Menozzi M; Santoro A; Barp N; Volpi S; Soffritti A; Pea F; Mussini C; Meschiari M
Antibiotics (Basel); 2023 Nov; 12(11):. PubMed ID: 37998841
[TBL] [Abstract][Full Text] [Related]
2. Dalbavancin as suppressive antibiotic therapy in patients with prosthetic infections: efficacy and safety.
Ruiz-Sancho A; Núñez-Núñez M; Castelo-Corral L; Martínez-Marcos FJ; Lois-Martínez N; Abdul-Aziz MH; Vinuesa-García D
Front Pharmacol; 2023; 14():1185602. PubMed ID: 37448966
[TBL] [Abstract][Full Text] [Related]
3. Dalbavancin as suppressive therapy for implant-related infections: a case series with therapeutic drug monitoring and review of the literature.
Lafon-Desmurs B; Gachet B; Hennart B; Valentin B; Roosen G; Degrendel M; Loiez C; Beltrand E; D'Elia P; Migaud H; Robineau O; Senneville E
Eur J Clin Microbiol Infect Dis; 2024 May; ():. PubMed ID: 38753112
[TBL] [Abstract][Full Text] [Related]
4. A descriptive case series of the relationship between maintenance of conservative PK/PD efficacy thresholds of dalbavancin over time and clinical outcome in long-term treatment of staphylococcal osteoarticular infections.
Gatti M; Viale P; Cojutti PG; Zamparini E; De Paolis M; Giannella M; Pea F; Tedeschi S
Int J Antimicrob Agents; 2023 May; 61(5):106773. PubMed ID: 36878410
[TBL] [Abstract][Full Text] [Related]
5. Off-Label Use of Dalbavancin for Sequential Treatment of Spondylodiscitis by Methicillin-Resistant
Mazzitelli M; Gatti M; Scaglione V; Mengato D; Trevenzoli M; Sattin A; Pea F; Cattelan AM
Antibiotics (Basel); 2022 Oct; 11(10):. PubMed ID: 36290035
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic Drug Monitoring of Dalbavancin in Real Life: A Two-Year Experience.
Cattaneo D; Fusi M; Colaneri M; Fusetti C; Genovese C; Giorgi R; Matone M; Merli S; Petri F; Gori A
Antibiotics (Basel); 2023 Dec; 13(1):. PubMed ID: 38247579
[TBL] [Abstract][Full Text] [Related]
7. Dalbavancin for treating prosthetic joint infections caused by Gram-positive bacteria: A proposal for a low dose strategy. A retrospective cohort study.
Buzón Martín L; Mora Fernández M; Perales Ruiz JM; Ortega Lafont M; Álvarez Paredes L; Morán Rodríguez MA; Fernández Regueras M; Machín Morón MA; Mejías Lobón G
Rev Esp Quimioter; 2019 Dec; 32(6):532-538. PubMed ID: 31642637
[TBL] [Abstract][Full Text] [Related]
8. Dalbavancin treatment for prosthetic joint infections in real-life: a national cohort study and literature review.
Matt M; Duran C; Courjon J; Lotte R; Moing VL; Monnin B; Pavese P; Chavanet P; Khatchatourian L; Tattevin P; Cattoir V; Lechiche C; Illes G; Lacassin-Beller F; Senneville E; Dinh A;
J Glob Antimicrob Resist; 2021 Jun; 25():341-345. PubMed ID: 33962065
[TBL] [Abstract][Full Text] [Related]
9. Expert Opinion on Dose Regimen and Therapeutic Drug Monitoring for Long-Term Use of Dalbavancin: Expert Review Panel.
Senneville E; Cuervo G; Gregoire M; Hidalgo-Tenorio C; Jehl F; Miro JM; Seaton A; Söderquist B; Soriano A; Thalhammer F; Pea F
Int J Antimicrob Agents; 2023 Nov; 62(5):106960. PubMed ID: 37633424
[TBL] [Abstract][Full Text] [Related]
10. Real-World Use of Dalbavancin in the Era of Empowerment of Outpatient Antimicrobial Treatment: A Careful Appraisal Beyond Approved Indications Focusing on Unmet Clinical Needs.
Gatti M; Andreoni M; Pea F; Viale P
Drug Des Devel Ther; 2021; 15():3349-3378. PubMed ID: 34376971
[TBL] [Abstract][Full Text] [Related]
11. Dalbavancin Efficacy and Impact on Hospital Length-of-Stay and Treatment Costs in Different Gram-Positive Bacterial Infections.
Poliseno M; Bavaro DF; Brindicci G; Luzzi G; Carretta DM; Spinarelli A; Messina R; Miolla MP; Achille TI; Dibartolomeo MR; Dell'Aera M; Saracino A; Angarano G; Favale S; D'Agostino C; Moretti B; Signorelli F; Taglietti C; Carbonara S
Clin Drug Investig; 2021 May; 41(5):437-448. PubMed ID: 33884583
[TBL] [Abstract][Full Text] [Related]
12. The current and future off-label uses of dalbavancin: a narrative review.
De Vito A; Fiore V; Colpani A; Zauli B; Fanelli C; Tiseo G; Occhineri S; Babudieri S; Falcone M; Madeddu G
Eur Rev Med Pharmacol Sci; 2023 Feb; 27(3):1222-1238. PubMed ID: 36808371
[TBL] [Abstract][Full Text] [Related]
13. Use of dalbavancin in infective endocarditis: a case series.
Guleri A; More R; Sharma R; Wong M; Abdelrahman A
JAC Antimicrob Resist; 2021 Sep; 3(3):dlab099. PubMed ID: 34396119
[TBL] [Abstract][Full Text] [Related]
14. Dalbavancin as sequential therapy in infective endocarditis: Real-life experience in elder and comorbid patients.
Aparicio-Minguijón E; Boán J; Terrón A; Heredia C; Puente C; Pérez-Jacoiste Asín A; Orellana MÁ; Domínguez L; Caro JM; López-Gude MJ; Aguilar-Blanco EM; Eixerés-Esteve A; López-Medrano F
Enferm Infecc Microbiol Clin (Engl Ed); 2024 Jun; ():. PubMed ID: 38902152
[TBL] [Abstract][Full Text] [Related]
15. Serum Bactericidal Activity Levels Monitor to Guide Intravenous Dalbavancin Chronic Suppressive Therapy of Inoperable Staphylococcal Prosthetic Valve Endocarditis: A Case Report.
Spaziante M; Franchi C; Taliani G; D'Avolio A; Pietropaolo V; Biliotti E; Esvan R; Venditti M
Open Forum Infect Dis; 2019 Nov; 6(11):ofz427. PubMed ID: 31737736
[TBL] [Abstract][Full Text] [Related]
16. Current trends in the real-life use of dalbavancin: report of a study panel.
Durante-Mangoni E; Gambardella M; Iula VD; De Stefano GF; Corrado MF; Esposito V; Gentile I; Coppola N
Int J Antimicrob Agents; 2020 Oct; 56(4):106107. PubMed ID: 32721599
[TBL] [Abstract][Full Text] [Related]
17. Multicenter clinical experience of real life Dalbavancin use in gram-positive infections.
Wunsch S; Krause R; Valentin T; Prattes J; Janata O; Lenger A; Bellmann-Weiler R; Weiss G; Zollner-Schwetz I
Int J Infect Dis; 2019 Apr; 81():210-214. PubMed ID: 30794940
[TBL] [Abstract][Full Text] [Related]
18. Dalbavancin as an alternative to traditional outpatient parenteral antimicrobial therapy for deep gram-positive infections - an observational, retrospective review.
Bao H; Igwilo-Alaneme R; Sonia F; Cowman K; Kahn M; Nori P
Ther Adv Infect Dis; 2024; 11():20499361241245523. PubMed ID: 38645297
[TBL] [Abstract][Full Text] [Related]
19. Use of Dalbavancin in Skin, Bone and Joint Infections: A Real-Life Experience in an Italian Center.
Brescini L; Della Martera F; Morroni G; Mazzanti S; Di Pietrantonio M; Mantini P; Candelaresi B; Pallotta F; Olivieri S; Iencinella V; Castelletti S; Cocci E; Polo RG; Veccia S; Cirioni O; Tavio M; Giacometti A
Antibiotics (Basel); 2021 Sep; 10(9):. PubMed ID: 34572711
[TBL] [Abstract][Full Text] [Related]
20. Dalbavancin plasma concentrations in 133 patients: a PK/PD observational study.
Hervochon C; Hennart B; Leroy AG; Corvec S; Boutoille D; Senneville É; Sotto A; Illes G; Chavanet P; Dubée V; Bleibtreu A; De Carné MC; Talarmin JP; Revest M; Castan B; Bellouard R; Dailly É; Allorge D; Dinh A; Le Turnier P; Gregoire M;
J Antimicrob Chemother; 2023 Dec; 78(12):2919-2925. PubMed ID: 37864551
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]